Amedeo Smart

Free Medical Literature Service

 

Amedeo

Gynecology
  Free Subscription

Articles published in
Eur J Cancer
    June 2026
  1. CASACCIA GIORDANO F, Lazzari R, Macchia G, Durante S, et al
    Hold the line: Local control strategies in oligoprogressive gynecologic cancers during systemic therapy.
    Eur J Cancer. 2026;244:116894.
    >> Share

  2. WAKKERMAN FC, Post CCB, Ortoft G, Hogdall E, et al
    No prognostic role for FIGO grading in mismatch repair deficient endometrial carcinoma.
    Eur J Cancer. 2026;244:116885.
    >> Share

  3. DAUCCIA C, Franzoi MA, Saura C, Hlauschek D, et al
    Body mass index in postmenopausal women with estrogen receptor-positive, HER2-negative early breast cancer: An exploratory analysis of the LORELEI trial.
    Eur J Cancer. 2026;244:116880.
    >> Share

  4. HEROLD N, Engel C, Speiser D, Ripperger T, et al
    Spectrum of double heterozygosity in individuals diagnosed with hereditary breast and ovarian cancer.
    Eur J Cancer. 2026;244:116874.
    >> Share

    May 2026
  5. CAPASSO I, Perrone E, Mancusi RL, Loverro M, et al
    Prognostic significance of lymphovascular space invasion extent across molecular classes in early-stage endometrial cancer: A large retrospective analysis.
    Eur J Cancer. 2026;243:116846.
    >> Share

  6. ELLIS LB, Tighe J, Bowden SJ, Kechagias KS, et al
    Diagnostic testing accuracy of DNA methylation tests for detection of high-grade cervical intraepithelial neoplasia and cervical cancer: A systematic review and meta-analysis.
    Eur J Cancer. 2026;243:116823.
    >> Share

  7. VAN DER KOLK WL, Landsbergen K, van der Zee AGJ, de Bock GH, et al
    FIGO 2021 depth of invasion measurement and missed lymph node involvement in microinvasive vulvar squamous cell carcinoma: Is the gain worth the cost?
    Eur J Cancer. 2026;239:116695.
    >> Share

    April 2026
  8. MARCHETTI C, Gultekin M, Sassu CM, Planchamp F, et al
    ESGO Consensus Statement on endometrial cancer prevention, risk reduction strategies, and management of women with Lynch syndrome.
    Eur J Cancer. 2026;240:116739.
    >> Share

    March 2026
  9. COLOMBO N, Parma G, Tasca G, Di Palma MP, et al
    Rational adjustment of dose to reduce adverse reactions (RADAR) in patients with platinum-sensitive recurrent ovarian cancer: Results from the phase II NEWTON trial (ENGOT-ov49).
    Eur J Cancer. 2026;239:116685.
    >> Share

  10. KIEVIET JJE, Pijnenborg JMA, van der Aa M, Werner HMJ, et al
    Country-of-birth disparities in high-grade endometrial cancer: A European-first population-based analysis on incidence, age at presentation, and survival in an equal-access health system in the Netherlands.
    Eur J Cancer. 2026;239:116698.
    >> Share

    February 2026
  11. BERARDI E, J van Driel W, H M Hermans R, N Gaarenstroom K, et al
    MRI in advanced ovarian cancer: multicentre MISSION trial.
    Eur J Cancer. 2026;238:116614.
    >> Share

  12. SCHEVENHOVEN VJC, Jansen EEL, Siebers AG, de Kok IMCM, et al
    Long-term cervical cancer risk following negative hrHPV-based versus negative cytology-based screening: A population-based study.
    Eur J Cancer. 2026;237:116601.
    >> Share

  13. PEDERSEN S, Colmorn LB, Ellebaek E, Kristensen SG, et al
    Impact of adjuvant anti-PD-1 immunotherapy on ovarian function in female patients with resectable melanoma: A prospective observational study.
    Eur J Cancer. 2026;237:116584.
    >> Share

    January 2026
  14. KASIUS JC, Kildal W, Vrede SW, Pijnenborg JMA, et al
    Response to letter Re: Surgical stage in the era of molecular profiling of endometrial cancer.
    Eur J Cancer. 2026;236:116268.
    >> Share

  15. NARDIN S, Bruzzone M, Arecco L, Chiappe E, et al
    Comparison of suboptimal versus adequate ovarian function suppression in premenopausal women with early breast cancer treated with adjuvant endocrine therapy: An exploratory analysis of two prospective studies.
    Eur J Cancer. 2026;236:116266.
    >> Share

  16. TYAGI B, Toppo L, Biradar A
    Letter Re: Surgical stage in the era of molecular profiling of endometrial cancer.
    Eur J Cancer. 2026;236:116267.
    >> Share

  17. LEONE ROBERTI MAGGIORE U, Fanfani F, Capasso I, Perrone E, et al
    Fertility-sparing vs hysterectomy for uterine STUMP: A pragmatic clinical study.
    Eur J Cancer. 2026;236:116260.
    >> Share

  18. NYBACK S, Poromaa IS, Lindman H, Hirschberg AL, et al
    Vaginal tamoxifen - A potential treatment option for vaginal atrophy symptoms in postmenopausal women who cannot use estrogen.
    Eur J Cancer. 2026;236:116261.
    >> Share

  19. SPATA A, Ribeiro JM, Vigneri P, Zambelli A, et al
    Comprehensive review of pregnancy associated breast cancer: Clinical features, molecular characteristics and novel therapies.
    Eur J Cancer. 2026;235:116230.
    >> Share

  20. WOODFORD R, Lord S, Decaria A, Simes J, et al
    Informative censoring in maintenance therapy trials for advanced ovarian cancer: An empirical assessment of its impact on treatment benefit.
    Eur J Cancer. 2026;235:116231.
    >> Share

    December 2025
  21. KASIUS JC, Kildal W, Vrede SW, Askautrud HA, et al
    Surgical stage in the era of molecular profiling of endometrial cancer.
    Eur J Cancer. 2025;233:116164.
    >> Share

  22. LIN Y, Chen X, Chen W, Sun Y, et al
    Letter to the editor Re: Immunotherapy and PARP inhibitors as first-line treatment in endometrial cancer: A systematic review and network meta-analysis.
    Eur J Cancer. 2025;233:116163.
    >> Share

    November 2025
  23. SECCHI M, Signorelli M, Rulli E, Maruccio M, et al
    Neoadjuvant chemotherapy followed by interval surgery versus primary debulking surgery in FIGO stage III-IV epithelial ovarian cancer: A systematic review and meta-analysis.
    Eur J Cancer. 2025;232:116116.
    >> Share

  24. PUJOL P, Roca L, Lortholary A, Lasset C, et al
    Letrozole to prevent breast cancer in postmenopausal women with BRCA1/2 mutations (LIBER study).
    Eur J Cancer. 2025;231:116101.
    >> Share

    October 2025
  25. LOMBAERS MS, Reijnen C, Sprik A, Bretova P, et al
    ENDORISK-2: A personalized Bayesian network for preoperative risk stratification in endometrial cancer, integrating molecular classification and preoperative myometrial invasion assessment.
    Eur J Cancer. 2025;231:116058.
    >> Share

  26. RAMESH-KUMAR D, Sanchez-Castillo A, Soler M, Martin-Tejera JF, et al
    Specific targeting of the pseudogene RPSAP52 reduces ovarian tumor growth in patient-derived orthoxenograft models.
    Eur J Cancer. 2025;230:116040.
    >> Share

    September 2025
  27. LI H, Sui T, He Q
    Letter Re: ENDOESTRO score: Where is the dark side? Evaluation of estrogen receptor expression cutoff in endometrial cancer molecular classification, an ambispective study.
    Eur J Cancer. 2025;230:115803.
    >> Share

  28. RAMOS-CASALLAS A, Cardona-Mendoza A, Perdomo-Lara SJ, Rico-Mendoza A, et al
    Performance evaluation of machine learning models in cervical cancer diagnosis: Systematic review and meta-analysis.
    Eur J Cancer. 2025;229:115768.
    >> Share

    August 2025
  29. HARDIE AN, Wenzel HHB, Schnack TH, Van der Aa MA, et al
    Response to Letter Re: Oncological outcomes after radical hysterectomy followed by adjuvant (chemo)radiation or no further treatment in women with cervical cancer FIGO 2018 IB2-IIA2- a multinational population-based cohort study.
    Eur J Cancer. 2025;228:115743.
    >> Share

  30. ZHANG Y, Kang Q, Qu R
    Letter Re: Oncological outcomes after radical hysterectomy followed by adjuvant (chemo)radiation or no further treatment in women with cervical cancer FIGO 2018 IB2-IIA2 - A multinational population-based cohort study.
    Eur J Cancer. 2025;228:115742.
    >> Share

  31. WANG L, Chang Q, Li M
    Letter Re: Risk of secondary myelodysplastic syndromes and acute myeloid leukaemia following poly (ADP-ribose) polymerase inhibitor treatment for advanced-stage recurrent ovarian cancer: A retrospective cohort study in England.
    Eur J Cancer. 2025;228:115740.
    >> Share

  32. CAPASSO I, Perrone E, Loverro M, Giannarelli D, et al
    Focal lymphovascular space invasion: Friend or foe? A large retrospective analysis on stage I endometrioid endometrial carcinomas.
    Eur J Cancer. 2025;228:115736.
    >> Share

  33. ALPERT A, Shirron N, Shirman Y, Goshen-Lago T, et al
    Deciphering the proteomic landscape of pregnancy-associated colorectal cancer.
    Eur J Cancer. 2025;228:115718.
    >> Share

  34. PERRONE E, Distefano E, Palmieri E, Giannarelli D, et al
    ENDOESTRO score: Where is the dark side? Evaluation of estrogen receptor expression cutoff in endometrial cancer molecular classification, an ambispective study.
    Eur J Cancer. 2025;227:115686.
    >> Share

    July 2025
  35. HARDIE AN, Wenzel HHB, Schnack TH, Van der Aa MA, et al
    Oncological outcomes after radical hysterectomy followed by adjuvant (chemo)radiation or no further treatment in women with cervical cancer FIGO 2018 IB2-IIA2 - A multinational population-based cohort study.
    Eur J Cancer. 2025;227:115664.
    >> Share

  36. BLONS H, Abdelli J, Landman S, Taly V, et al
    Predictive value of BRCA1/RAD51C methylation in HGSOC - An ancillary study of the PAOLA-1/ENGOT-ov25 phase 3 trial.
    Eur J Cancer. 2025;225:115534.
    >> Share

    June 2025
  37. CAPOZZI VA, Perrone E, Scarpelli E, Tarantino V, et al
    Exploring isolated tumor cells entity in endometrial cancer.
    Eur J Cancer. 2025;225:115586.
    >> Share

  38. COLEMAN RL, Fleming GF, Brady MF, Swisher EM, et al
    Veliparib concomitant with first-line chemotherapy and as maintenance therapy in ovarian cancer: Final overall survival and disease-related symptoms results.
    Eur J Cancer. 2025;225:115587.
    >> Share

  39. LEDERMANN JA, Oza AM, Lorusso D, Aghajanian C, et al
    Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial.
    Eur J Cancer. 2025;225:115584.
    >> Share

    May 2025
  40. PORTER JM, Jin C, Churchman M, Croy I, et al
    Antibody drug conjugate targets are highly differentially expressed across the major types of ovarian cancer.
    Eur J Cancer. 2025;224:115522.
    >> Share

  41. WANG H, Wang N
    Letter Re: Induction chemotherapy followed by chemoradiation in locally advanced cervical cancer: Quality of life outcomes of the GCIG INTERLACE trial.
    Eur J Cancer. 2025 May 19:115515. doi: 10.1016/j.ejca.2025.115515.
    >> Share

  42. STEVENTON L, Nicum S, Chambers P, Man K, et al
    Corrigendum to "Risk of secondary myelodysplastic syndromes and acute myeloid leukaemia following poly(ADP-ribose) polymerase inhibitor treatment for advanced-stage ovarian cancer: A retrospective cohort study" [Eur J Cancer 222 (2025) 115472].
    Eur J Cancer. 2025;223:115492.
    >> Share

  43. HOLLIS RL, Herrington CS, Gourley C
    Response to letter RE: Somatic BRCA1/2 mutations are associated with a similar survival advantage to their germline counterparts in tubo-ovarian high grade serous carcinoma.
    Eur J Cancer. 2025 May 5:115491. doi: 10.1016/j.ejca.2025.115491.
    >> Share

  44. KARABUGA B, Baskurt K, Mammadzada N, Sutcuoglu O, et al
    Letter RE: Somatic BRCA1/2 mutations are associated with a similar survival advantage to their germline counterparts in tubo-ovarian high-grade serous carcinoma.
    Eur J Cancer. 2025 May 4:115490. doi: 10.1016/j.ejca.2025.115490.
    >> Share

    April 2025
  45. FIORE M, Ljevar S, Raut CP, Personeni G, et al
    Impact and safety of pregnancy on desmoid fibromatosis management in the era of active surveillance. An international multicenter retrospective observational study.
    Eur J Cancer. 2025;222:115474.
    >> Share

  46. STEVENTON L, Nicum S, Chambers P, Man K, et al
    Risk of secondary myelodysplastic syndromes and acute myeloid leukaemia following poly(ADP-ribose) polymerase inhibitor treatment for advanced-stage recurrent ovarian cancer: A retrospective cohort study in England.
    Eur J Cancer. 2025;222:115472.
    >> Share

  47. LIU W, Yang Y
    Letter re: The prognostic and clinical significance of substantial lymphovascular space invasion in early-stage endometrial carcinoma.
    Eur J Cancer. 2025 Apr 25:115446. doi: 10.1016/j.ejca.2025.115446.
    >> Share

  48. ONAL C, Elmali A, Demirhan B, Guler OC, et al
    Letter comments on: "Induction chemotherapy followed by chemoradiation in locally advanced cervical cancer: Quality of life outcomes of the GCIG INTERLACE trial".
    Eur J Cancer. 2025 Apr 22:115448. doi: 10.1016/j.ejca.2025.115448.
    >> Share

  49. EMINOWICZ G, Vaja S, Hackshaw A, McCormack M, et al
    Response to letter Re: Induction chemotherapy followed by chemoradiation in locally advanced cervical cancer: Quality of life outcomes of the GCIG INTERLACE trial.
    Eur J Cancer. 2025 Apr 22:115449. doi: 10.1016/j.ejca.2025.115449.
    >> Share

  50. BIGANZOLI G, Isnaldi E, Richard F, Marano G, et al
    Prognostic relation of body mass index on extended aromatase inhibition treatment in postmenopausal patients with estrogen receptor positive breast cancer: A retrospective analysis of the SOLE trial.
    Eur J Cancer. 2025;222:115438.
    >> Share

  51. MAGATON IM, Blondeaux E, Hamy AS, Linn S, et al
    Assisted reproductive technology in young BRCA carriers with a pregnancy after breast cancer: An international cohort study.
    Eur J Cancer. 2025;222:115434.
    >> Share

  52. LEIBETSEDER A, Berghoff AS
    Response to letter commenting on "Association of pregnancy with tumour progression in patients with glioma".
    Eur J Cancer. 2025 Apr 9:115411. doi: 10.1016/j.ejca.2025.115411.
    >> Share

  53. DANG C, Liu P, Yu X
    Letter Re: Association of pregnancy with tumour progression in patients with glioma.
    Eur J Cancer. 2025 Apr 4:115410. doi: 10.1016/j.ejca.2025.115410.
    >> Share

    March 2025
  54. MAENG CH, Han K, Hong JY, Park JH, et al
    Association between premature menopause and the risk of biliary tract cancer: A nationwide cohort study.
    Eur J Cancer. 2025;220:115387.
    >> Share

  55. EMINOWICZ G, Vaja S, Gallardo D, Kent C, et al
    Induction chemotherapy followed by chemoradiation in locally advanced cervical cancer: Quality of life outcomes of the GCIG INTERLACE trial.
    Eur J Cancer. 2025;220:115375.
    >> Share

  56. SIITONEN H, Joensuu J, Savolainen-Peltonen H, Gissler M, et al
    Update of the impact of menopausal hormone therapy on breast cancer risk.
    Eur J Cancer. 2025;220:115340.
    >> Share

  57. CAPASSO I, Perrone E, Duranti S, Giannarelli D, et al
    Are all mismatch repair deficient endometrial cancers created equal? A large, retrospective, tertiary center experience.
    Eur J Cancer. 2025;220:115344.
    >> Share

    February 2025
  58. VILLACAMPA G, Eminowicz G, Navarro V, Carita L, et al
    Immunotherapy and PARP inhibitors as first-line treatment in endometrial cancer: A systematic review and network meta-analysis.
    Eur J Cancer. 2025;220:115329.
    >> Share

  59. STEGER K, Fiegl H, Feroz B, Leitner K, et al
    Differences in immunogenicity of TP53-mutated cancers with low tumor mutational burden (TMB) A study on TP53mut endometrial-, ovarian- and triple-negative breast cancer.
    Eur J Cancer. 2025;219:115320.
    >> Share

  60. VERGOTE I, Copeland LJ, Van Gorp T, Laenen A, et al
    Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study.
    Eur J Cancer. 2025;219:115306.
    >> Share

  61. HASEGAWA K, Nishio S, Yamamoto K, Fujiwara H, et al
    Tegafur-uracil maintenance chemotherapy post-chemoradiotherapy for cervical cancer: Randomized trial.
    Eur J Cancer. 2025;219:115304.
    >> Share

  62. HOLLIS RL, Churchman M, Grimes GR, Meynert AM, et al
    Somatic BRCA1/2 mutations are associated with a similar survival advantage to their germline counterparts in tubo-ovarian high grade serous carcinoma.
    Eur J Cancer. 2025;219:115299.
    >> Share

    January 2025
  63. LI Z, Peng J, Zhang B, Zhao C, et al
    The prognostic and clinical significance of substantial lymphovascular space invasion in early-stage endometrial carcinoma.
    Eur J Cancer. 2025;218:115258.
    >> Share

  64. LEIBETSEDER A, Mair MJ, Serra AS, Spiro Z, et al
    Association of pregnancy with tumour progression in patients with glioma.
    Eur J Cancer. 2025;218:115259.
    >> Share

  65. OAKNIN A, Monk BJ, de Melo AC, Kim HS, et al
    Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial.
    Eur J Cancer. 2025;216:115146.
    >> Share

    December 2024
  66. MARME F, Krieghoff-Henning EI, Kiehl L, Wies C, et al
    Predicting benefit from PARP inhibitors using deep learning on H&E-stained ovarian cancer slides.
    Eur J Cancer. 2024;216:115199.
    >> Share

  67. QUESADA S, Penault-Llorca F, Matias-Guiu X, Banerjee S, et al
    Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnostics.
    Eur J Cancer. 2024;215:115169.
    >> Share

  68. HEMMINGSEN CH, Kjaer SK, Hjorth S, Norby U, et al
    Maternal use of hormonal contraception and risk of childhood leukemia: A Scandinavian population-based cohort study.
    Eur J Cancer. 2024;215:115168.
    >> Share

    November 2024
  69. MATIAS-GUIU X, Lax S, Raspollini MR, Palacios J, et al
    FIGO 2023 staging for endometrial cancer, when, if it is not now?
    Eur J Cancer. 2024;213:115115.
    >> Share

    October 2024
  70. WENZEL HHB, Schnack TH, Van der Aa MA, Jensen PT, et al
    Risk factors for lymph node metastasis in women with FIGO 2018 IA cervical cancer with a horizontal spread of > 7 mm.
    Eur J Cancer. 2024;212:115063.
    >> Share

  71. GIANNOPOULOS S, Naeem S, Nasioudis D, Gossner G, et al
    Value of surgical lymph node assessment for patients with vulvar melanoma.
    Eur J Cancer. 2024;210:114303.
    >> Share

    September 2024
  72. BIZZARRI N, Querleu D, Ramirez PT, Dostalek L, et al
    Survival associated with the use of sentinel lymph node in addition to lymphadenectomy in early-stage cervical cancer treated with surgery alone: A sub-analysis of the Surveillance in Cervical CANcer (SCCAN) collaborative study.
    Eur J Cancer. 2024;211:114310.
    >> Share

  73. VULSTEKE C, Chambers SK, Perez MJR, Chan JK, et al
    Tolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy.
    Eur J Cancer. 2024;208:114157.
    >> Share

    August 2024
  74. BOLLINO M, Geppert B, Lonnerfors C, Masback A, et al
    Prevalence and size of pelvic sentinel lymph node metastases in endometrial cancer.
    Eur J Cancer. 2024;209:114265.
    >> Share

    July 2024
  75. FASCHING PA, Hack CC, Nabieva N, Maass N, et al
    Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole.
    Eur J Cancer. 2024;209:114239.
    >> Share

  76. SOUTHWORTH E, Thomson JP, Croy I, Churchman M, et al
    Whole exome sequencing reveals diverse genomic relatedness between paired concurrent endometrial and ovarian carcinomas.
    Eur J Cancer. 2024;208:114205.
    >> Share

    May 2024
  77. ROMA C, Esposito Abate R, Sacco A, Califano D, et al
    Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A/MaNGO-OV2 trial.
    Eur J Cancer. 2024;206:114127.
    >> Share

    April 2024
  78. BOLLINO M, Geppert B, Lonnerfors C, Persson J, et al
    A selective anatomically based lymph node sampling can replace a side specific pelvic lymphadenectomy in endometrial cancer with failed sentinel node mapping.
    Eur J Cancer. 2024;204:114049.
    >> Share

  79. GRAVBROT N, Weil CR, DeCesaris CM, Gaffney DK, et al
    Corrigendum to "Differentiation of survival outcomes by anatomic involvement and histology with the revised 2023 International Federation of Gynecology and Obstetrics staging system for endometrial cancer" Eur. J. Cancer (201) (April) 2024, 113913.
    Eur J Cancer. 2024 Apr 2:114017. doi: 10.1016/j.ejca.2024.114017.
    >> Share

    March 2024
  80. TUNINETTI V, Virano E, Salutari V, Ricotti A, et al
    Real-life efficacy and safety of cemiplimab in advanced cervical cancer from a nominal use program in Italy: The MITO 44 study.
    Eur J Cancer. 2024;203:114039.
    >> Share

  81. BOIDOT R, Blum MGB, Wissler MP, Gottin C, et al
    Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer.
    Eur J Cancer. 2024;202:113978.
    >> Share

    November 2023
  82. SCHWAMEIS R, Fanfani F, Ebner C, Zimmermann N, et al
    Verification of the prognostic precision of the new 2023 FIGO staging system in endometrial cancer patients - An international pooled analysis of three ESGO accredited centres.
    Eur J Cancer. 2023;193:113317.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016